{
    "clinical_study": {
        "@rank": "58546", 
        "acronym": "HiTS", 
        "arm_group": {
            "arm_group_label": "Ustekinumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ustekinumab is effective in the treatment\n      of moderate to severe hidradenitis suppurativa."
        }, 
        "brief_title": "A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hidradenitis Suppurativa", 
        "condition_browse": {
            "mesh_term": [
                "Hidradenitis", 
                "Hidradenitis Suppurativa"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Hidradenitis suppurativa Hurley stage II or III\n\n          -  No response to conventional local and oral antibiotics, or immunnesuppressive\n             medication, or TNF-alpha inhibitors or surgery\n\n          -  The patient has to be able to complete a dutch questionnaire\n\n          -  Informed consent must be obtained\n\n        Exclusion Criteria:\n\n          -  Not able to complete a Dutch questionnaire\n\n          -  Pregnancy or breast feeding\n\n          -  Active hepatitis B or C infection, HIV or tuberculosis\n\n          -  Treatment with biologics or other immunosuppressive medicine in the previous 3 months\n\n          -  Malignancies in the last 10 years with the exception of basal cell carcinoma\n\n          -  Demyelinating disorders\n\n          -  Heart failure\n\n          -  Known allergy to ustekinumab or to its preservatives\n\n          -  Live vaccins in the next 3 months Sever liver or renal failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704534", 
            "org_study_id": "662507", 
            "secondary_id": "2011-002091-16"
        }, 
        "intervention": {
            "arm_group_label": "Ustekinumab", 
            "description": "subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28", 
            "intervention_name": "Ustekinumab", 
            "intervention_type": "Drug", 
            "other_name": "Stelara"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hidradenitis suppurativa", 
            "Acne ectopica", 
            "Inverse acne", 
            "Ustekinumab", 
            "Stelara"
        ], 
        "lastchanged_date": "June 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands", 
                    "zip": "9700RB"
                }, 
                "name": "University Medical Centre Groningen"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)", 
        "overall_official": {
            "affiliation": "University Medical Centre Groningen", 
            "last_name": "Barbara Horv\u00e1th, MD-PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical response is defined as an improvement of the Sartorius score of at least 50%", 
            "measure": "Change in Sartorius score", 
            "safety_issue": "No", 
            "time_frame": "76 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704534"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Groningen", 
            "investigator_full_name": "Barbara Horv\u00e1th, Principal Investigator", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Medical Centre Groningen", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen-Cilag B.V.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Medical Centre Groningen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}